Themis partners with CEPI to develop Lassa, MERS vaccines

Themis Bioscience GmbH (Vienna, Austria) will receive up to $37.5 million in non-dilutive funding from the Coalition for Epidemic Preparedness Innovations to support development of vaccines for Lassa fever and Middle East respiratory syndrome (MERS).

CEPI said the deal marks the coalition’s first company agreement since its founding last year to accelerate vaccine development for emerging infectious diseases...